The Connectivity Map: a new tool for biomedical research
The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
The ultimate objective of biomedical research is to connect human diseases with the genes that underlie them and drugs that treat them. But this remains a daunting task, and even the most inspired researchers still have to resort to laborious screens of genetic or chemical libraries. What if at least some parts of this screening process could be systematized and centralized? And hits found and hypotheses generated with something resembling an internet search engine? These are the questions the Connectivity Map project set out to answer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, they do not support complex molecular readouts such as transcriptome profiling, which is one of the most comprehensive and informative measures of cellular response 5 .”
From Pooled CRISPR screening with single-cell transcriptome readout. (2017) · cites this paper as [5]
In the citing paper
“This tool allowed researchers to investigate genome-wide effects of GHK and establish that GHK-Cu is able to up- and down-regulate a significant number of human genes.”
From Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data (2018) · cites this paper as [3]
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Gene Expression Omnibus: NCBI gene expression and hybridization array data repository
Edgar, R. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.1.207 · Cited by 13,288
Golub, T. R., Slonim, D. K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J. P., Coller, H., Loh, M. L., Downing, J. R., Caligiuri, M. A., et al. (1999) · Science · doi:10.1126/science.286.5439.531 · Cited by 11,516
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,782
Lamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J.-P., Subramanian, A., Ross, K. N., et al. (2006) · Science · doi:10.1126/science.1132939 · Cited by 5,257
Self-citationDruker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243 · cited 1×
“) to rationality (chronic myeloid leukaemia–BCR-ABL–imatini”
Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12953 · Cited by 3,625
ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform
Rhodes, D. R., Yu, J., Shanker, K., Deshpande, N., Varambally, R., Ghosh, D., Barrette, T., Pander, A., & Chinnaiyan, A. M. (2004) · Neoplasia · doi:10.1016/s1476-5586(04)80047-2 · Cited by 3,612
A gene atlas of the mouse and human protein-encoding transcriptomes
Su, A. I., Wiltshire, T., Batalov, S., Lapp, H., Ching, K. A., Block, D., Zhang, J., Soden, R., Hayakawa, M., Kreiman, G., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400782101 · Cited by 3,475
Cited by
Natural Products for Drug Discovery in the 21st Century: Innovations for Novel Drug Discovery
Thomford, N. E., Senthebane, D. A., Rowe, A., Munro, D., Seele, P., Maroyi, A., & Dzobo, K. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061578 · Cited by 1,241
Pooled CRISPR screening with single-cell transcriptome readout.
Datlinger, P., Rendeiro, A. F., Schmidl, C., Krausgruber, T., Traxler, P., Klughammer, J., Schuster, L. C., Kuchler, A., Alpar, D., & Bock, C. (2017) · Nature Methods · doi:10.1038/nmeth.4177 · Cited by 1,096
ChEA: transcription factor regulation inferred from integrating genome-wide ChIP-X experiments
Lachmann, A., Xu, H., Krishnan, J., Berger, S. I., Mazloom, A. R., & Ma'ayan, A. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq466 · Cited by 1,029
Survivin, cancer networks and pathway-directed drug discovery
Altieri, D. C. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2293 · Cited by 994
PREDICT: a method for inferring novel drug indications with application to personalized medicine
Gottlieb, A., Stein, G. Y., Ruppin, E., & Sharan, R. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.26 · Cited by 881
Discovery of drug mode of action and drug repositioning from transcriptional responses
Iorio, F., Bosotti, R., Scacheri, E., Belcastro, V., Mithbaokar, P., Ferriero, R., Murino, L., Tagliaferri, R., Brunetti-Pierri, N., Isacchi, A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000138107 · Cited by 816
“Among the most promising approaches are the ones based on “ gene signatures ” (11, 12), i.e., subset of genes whose differential expression can be used as a marker of the activity of a given pathway, disease or compound.”
BackgroundMethodSystematic integration of biomedical knowledge prioritizes drugs for repurposing
Himmelstein, D. S., Lizee, A., Hessler, C., Brueggeman, L., Chen, S. L., Hadley, D., Green, A., Khankhanian, P., & Baranzini, S. E. (2017) · eLife · doi:10.7554/elife.26726 · Cited by 666
“…et al., 2011 ; Li and Lu, 2012 ), disease-disease similarity ( Gottlieb et al., 2011 ; Chiang and Butte, 2009 ), transcriptional signatures ( Lamb, 2007 ; Qu and Rajpal, 2012 ; Cheng et al., 2014 ; Lamb et al., 2006 ; Iorio et al., 2013 ), protein interactions ( Guney et al., 2016 ),…”
BackgroundThe Clinical Relevance of Cancer Cell Lines
Gillet, J.-P., Varma, S., & Gottesman, M. M. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt007 · Cited by 599
Computational approaches in target identification and drug discovery
Katsila, T., Spyroulias, G. A., Patrinos, G. P., & Matsoukas, M.-T. (2016) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2016.04.004 · Cited by 390
“…expression data from cultured human cells treated with bioactive small molecules and simple pattern-matching algorithms that together enable the discovery of functional connections between drugs, genes and diseases through the transitory feature of common gene-expression changes [26].”
BackgroundJarada, T. N., Rokne, J. G., & Alhajj, R. (2020) · Journal of Cheminformatics · doi:10.1186/s13321-020-00450-7 · Cited by 384
Drug repurposing for antimicrobial discovery
Farha, M. A., & Brown, E. D. (2019) · Nature Microbiology · doi:10.1038/s41564-019-0357-1 · Cited by 360
The emerging role of mass spectrometry-based proteomics in drug discovery
Meissner, F., Geddes-McAlister, J., Mann, M., & Bantscheff, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00409-3 · Cited by 341
Computational solutions for omics data
Berger, B., Peng, J., & Singh, M. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3433 · Cited by 346
“Large-scale gene expression investigations have had preliminary success at elucidating phenotypic gene expression signals 102–104 and applying those signals to downstream analyses, such as drug repurposing 104,105 .”
Backgroundvan Baarlen, P., Troost, F., van der Meer, C., Hooiveld, G., Boekschoten, M., Brummer, R. J. M., & Kleerebezem, M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000079107 · Cited by 334
“Connectivity-map (ConnMap) analysis enables the search for biologically relevant connections between gene-expression profiles and three different but strongly interconnected types of information: (i) high-throughput expression profiles of human cell lines after treatment with (ii) biologically active molecules that ar…”
BackgroundHeterogeneity of Alcohol Use Disorder: Understanding Mechanisms to Advance Personalized Treatment
Litten, R. Z., Ryan, M. L., Falk, D. E., Reilly, M., Fertig, J. B., & Koob, G. F. (2015) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.12669 · Cited by 330
Ezzat, A., Wu, M., Li, X.-L., & Kwoh, C.-K. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bby002 · Cited by 314
“Types of data that are available for drugs and may be used for training DTI classifiers include—but are not limited to—graphical representations of drugs’ chemical structures [31], side effects [32], Anatomical Therapeutic Chemical (ATC) codes [33] and gene expression responses to drugs [34].”
BackgroundHong, Y., Downey, T., Eu, K. W., Koh, P. K., & Cheah, P. Y. (2010) · Clinical & Experimental Metastasis · doi:10.1007/s10585-010-9305-4 · Cited by 319
“This map provides an in silico method to connect human diseases with the genes that underlie them and drugs that treat them [16].”
MethodDuan, Q., Flynn, C., Niepel, M., Hafner, M., Muhlich, J. L., Fernandez, N. F., Rouillard, A. D., Tan, C. M., Chen, E. Y., Golub, T. R., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku476 · Cited by 314
“Gene expression-based high-throughput screening (GE-HTS) has the potential to transform biomedicine and accelerate drug discovery by linking many bioactive molecular perturbations to their cellular phenotypes through the molecular regulatory mechanisms those perturbations induce (1,2).”
BackgroundHuman Disease-Drug Network Based on Genomic Expression Profiles
Hu, G., & Agarwal, P. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006536 · Cited by 310
“This enables an automated, somewhat comprehensive monitoring of the changes of various molecular components associated with different disease states and drug treatments, therefore enables the characterization of disease and drug effects, and an elucidation of their relationships at a molecular systems level [6–12].”
BackgroundThe Role of Natural Products as Sources of Therapeutic Agents for Innovative Drug Discovery
Dzobo, K. (2022) · Comprehensive Pharmacology · doi:10.1016/b978-0-12-820472-6.00041-4 · Cited by 256
“The connectivity map associates drug gene signatures with disease-associated gene signatures, thus allowing the identification of compounds that may reverse the disease gene signature (Beck et al., 2016; Brum et al., 2015; Lamb, 2007).”
InfluentialJosset, L., Menachery, V. D., Gralinski, L. E., Agnihothram, S., Sova, P., Carter, V. S., Yount, B. L., Graham, R. L., Baric, R. S., & Katze, M. G. (2013) · mBio · doi:10.1128/mbio.00165-13 · Cited by 293
“To this end, we used Connectivity Map (cmap), which is a database of more than 1,309 drug transcriptional signatures in several cell lines (22).”
BackgroundMethodInfluentialDrug repurposing in oncology—patient and health systems opportunities
Bertolini, F., Sukhatme, V. P., & Bouche, G. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.169 · Cited by 294
A network view of disease and compound screening
Schadt, E. E., Friend, S. H., & Shaywitz, D. A. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2826 · Cited by 291
A Bayesian machine learning approach for drug target identification using diverse data types
Madhukar, N. S., Khade, P. K., Huang, L., Gayvert, K., Galletti, G., Stogniew, M., Allen, J. E., Giannakakou, P., & Elemento, O. (2019) · Nature Communications · doi:10.1038/s41467-019-12928-6 · Cited by 265
Xiong, D.-D., Dang, Y.-W., Lin, P., Wen, D.-Y., He, R.-Q., Luo, D.-Z., Feng, Z.-B., & Chen, G. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1593-5 · Cited by 280
Thomas, R. S., Philbert, M. A., Auerbach, S. S., Wetmore, B. A., Devito, M. J., Cote, I., Rowlands, J. C., Whelan, M. P., Hays, S. M., Andersen, M. E., et al. (2013) · Toxicological Sciences · doi:10.1093/toxsci/kft178 · Cited by 272
“Alternatively, in vitro transcriptomic measurements could also be performed in concentration-response format across a panel of cell lines that express a diverse range of cellular targets and pathways (Lamb, 2007).”
Transcriptional data: a new gateway to drug repositioning?
Iorio, F., Rittman, T., Ge, H., Menden, M., & Saez-Rodriguez, J. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2012.07.014 · Cited by 237
Iljin, K., Ketola, K., Vainio, P., Halonen, P., Kohonen, P., Fey, V., Grafström, R. C., Perälä, M., & Kallioniemi, O. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1035 · Cited by 240
“on gene expression, Connectivity Map 02 was used (21).”
MethodKang, B. H., Plescia, J., Song, H. Y., Meli, M., Colombo, G., Beebe, K., Scroggins, B., Neckers, L., & Altieri, D. C. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37613 · Cited by 240
“Such connectivity maps, linking together multiple signaling pathways (12), may more faithfully recapitulate the tumor tactics responsible for treatment failure, including redundancy, buffering, and modularity into semiautonomous subnetworks (6).”
BackgroundChen, S., Liu, X., Peng, C., Tan, C., Sun, H., Liu, H., Zhang, Y., Wu, P., Cui, C., Liu, C., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.02.007 · Cited by 232
Computational network biology: Data, models, and applications
Liu, C., Ma, Y., Zhao, J., Nussinov, R., Zhang, Y.-C., Cheng, F., & Zhang, Z.-K. (2020) · Physics Reports · doi:10.1016/j.physrep.2019.12.004 · Cited by 227
Pham, T.-H., Qiu, Y., Zeng, J., Xie, L., & Zhang, P. (2021) · Nature Machine Intelligence · doi:10.1038/s42256-020-00285-9 · Cited by 217
Combining Drug and Gene Similarity Measures for Drug-Target Elucidation
Perlman, L., Gottlieb, A., Atias, N., Ruppin, E., & Sharan, R. (2011) · Journal of Computational Biology · doi:10.1089/cmb.2010.0213 · Cited by 218
“The connectivity map project [43] is an innovative framework that aims to relate drugs, genes and diseases via comparison of their gene-expression profiles or signatures, to a large database of signatures and using pattern-matching tools to reveal significant similarities among these signatures.”
High throughput toxicity screening and intracellular detection of nanomaterials
Collins, A. R., Annangi, B., Rubio, L., Marcos, R., Dorn, M., Merker, C., Estrela‐Lopis, I., Cimpan, M. R., Ibrahim, M., Cimpan, E., et al. (2017) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1413 · Cited by 207
Lagunin, A. A., Dubovskaja, V. I., Rudik, A. V., Pogodin, P. V., Druzhilovskiy, D. S., Gloriozova, T. A., Filimonov, D. A., Sastry, N. G., & Poroikov, V. V. (2018) · PLOS ONE · doi:10.1371/journal.pone.0191838 · Cited by 199
“Connectivity map approach—comparison of drug-induced gene signatures given on tumour cells [15–19]; 3.”
Xie, L., Xie, L., Kinnings, S. L., & Bourne, P. E. (2012) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134630 · Cited by 202
Marquardt, J. U., Galle, P. R., & Teufel, A. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.07.007 · Cited by 195
“The Connectivity map is a publically available and powerful tool that enables discovery of functional connections between drugs and genes using a collection of genome-wide transcriptional expression data from cultured human cells treated with bioactive small molecules [39,40].”
BackgroundLi, J., Zhu, X., & Chen, J. Y. (2009) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000450 · Cited by 185
“recently established a systematic approach to build connectivity maps using gene-expression profile information as the common vocabulary that connects small molecules, genes, and diseases [5].”
BackgroundTang, J., & Aittokallio, T. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990470 · Cited by 175
“A notable transcriptomics-based ongoing effort is the Connectivity Map (CMap), where the transcriptional profiles in five human cancer cell lines were originally profiled to assess the phenotypic changes brought about by more than 1000 bioactive small molecules [77].”
BackgroundBuriani, A., Garcia-Bermejo, M. L., Bosisio, E., Xu, Q., Li, H., Dong, X., Simmonds, M. S. J., Carrara, M., Tejedor, N., Lucio-Cazana, J., et al. (2012) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2012.01.055 · Cited by 184
“This endows metabonomics with a holistic view, making it closer to TCM thinking and particularly fit to study pharmacological and toxicological effects of CHM (Lao et al., 2009; Wang et al., 2005, 2011a,b,c; Zhang et al., 2010).”
New wirings in the survivin networks
Altieri, D. C. (2008) · Oncogene · doi:10.1038/onc.2008.303 · Cited by 181
“This approach (Lamb, 2007) has been used to represent the ‘nodal’ properties of survivin, and tentatively define its position at the crossroads of disparate molecular networks of cell division, subcellular trafficking, transcriptional responses, intracellular signaling and cell death (Altieri, 2008).”
McFarland, J. M., Paolella, B. R., Warren, A., Geiger-Schuller, K., Shibue, T., Rothberg, M., Kuksenko, O., Colgan, W. N., Jones, A., Chambers, E., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17440-w · Cited by 173
Drug repurposing for breast cancer therapy: Old weapon for new battle
Aggarwal, S., Verma, S. S., Aggarwal, S., & Gupta, S. C. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.09.012 · Cited by 163
“The similar gene expression profile for drug phenotype in patients with different diseases as mapped by connectivity map (cMap), Library Integrated Network based Cellular Signatures (LINCS), expression signatures may have similar therapeutic applications [50] [51] [52] .”
Reconstruction of the tumor spatial microenvironment along the malignant-boundary-nonmalignant axis
Xun, Z., Ding, X., Zhang, Y., Zhang, B., Lai, S., Zou, D., Zheng, J., Chen, G., Su, B., Han, L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36560-7 · Cited by 162
“Based ontheidenti fi cationof37up-regulatedand20down-regulatedgenesin the tumor boundary compared to other regions, we queried this signature and subsequently mapped the genes to the Connectivity Map (CMAP) 72 .”
Biological targets and mechanisms of action of natural products from marine cyanobacteria
Salvador-Reyes, L. A., & Luesch, H. (2015) · Natural Product Reports · doi:10.1039/c4np00104d · Cited by 162
Systems Pharmacology in Small Molecular Drug Discovery
Zhou, W., Wang, Y., Lu, A., & Zhang, G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17020246 · Cited by 162
In silico polypharmacology of natural products
Fang, J., Liu, C., Wang, Q., Lin, P., & Cheng, F. (2017) · Briefings in Bioinformatics · doi:10.1093/bib/bbx045 · Cited by 199
TAZ Expression as a Prognostic Indicator in Colorectal Cancer
Yuen, H.-F., McCrudden, C. M., Huang, Y.-H., Tham, J. M., Zhang, X., Zeng, Q., Zhang, S.-D., & Hong, W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054211 · Cited by 158
“expression of genes that are co-regulated in TAZ-AXL-CTGF coexpressing aggressive colon cancer [39,40,41].”
BackgroundRole of artificial intelligence in revolutionizing drug discovery
Rehman, A. U., Li, M., Wu, B., Ali, Y., Rasheed, S., Shaheen, S., Liu, X., Luo, R., & Zhang, J. (2024) · Fundamental Research · doi:10.1016/j.fmre.2024.04.021 · Cited by 209
“BANDIT utilizes over 20 million data points from six distinct data types, including drug efficacies, post-treatment responses, bioassay results [ 81 , 82 ], and known targets [ 83 , 84 ].”
Salinomycin inhibits prostate cancer growth and migration via induction of oxidative stress
Ketola, K., Hilvo, M., Hyötyläinen, T., Vuoristo, A., Ruskeepää, A.-L., Orešič, M., Kallioniemi, O., & Iljin, K. (2012) · British Journal of Cancer · doi:10.1038/bjc.2011.530 · Cited by 159
“Connectivity Map 02 was used to identify drugs with similar or opposite effects on gene expression (Lamb, 2007).”
MethodMav, D., Shah, R. R., Howard, B. E., Auerbach, S. S., Bushel, P. R., Collins, J. B., Gerhold, D. L., Judson, R. S., Karmaus, A. L., Maull, E. A., et al. (2018) · PLOS ONE · doi:10.1371/journal.pone.0191105 · Cited by 155
Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data
Pickart, L., & Margolina, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071987 · Cited by 158
“The Broad Institute of MIT and Harvard (Cambridge, MA, USA) has created the Connectivity Map—a publicly available library of transcriptional responses to known perturbagens, substances that modulate gene expression [3].”
BackgroundTargeting MTHFD2 in acute myeloid leukemia
Pikman, Y., Puissant, A., Alexe, G., Furman, A., Chen, L. M., Frumm, S. M., Ross, L., Fenouille, N., Bassil, C. F., Lewis, C. A., et al. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20151574 · Cited by 159
“The MTH FD2 hairpin knockdown signature (MTH FD2-trt.sh) was downloaded from the LIN CS-CMap/L1000 database (Lamb et al., 2006; Lamb, 2007).”
MethodMachine learning in the prediction of cancer therapy
Rafique, R., Islam, S. M. R., & Kazi, J. U. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.07.003 · Cited by 173
“Similarly, Cuvitoglu et al. extracted the drug perturbation set of genes for each drug from the transcriptome profile of Cmap data [131] and calculated six different features: the distance between two drugs (M1), the mutual information about biological processes (M2), the gene ontology similarity…”
BackgroundStructure-based systems biology for analyzing off-target binding
Xie, L., Xie, L., & Bourne, P. E. (2011) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2011.01.004 · Cited by 163
“A number of computational methodologies have been developed where relate putative protein targets through their ligand chemistry [15,16] or biological profiles (e.g., binding activities [17], expression profiles [18,19], side-effects [20]).”
BackgroundWinck, F. V., Ribeiro, A. C. P., Domingues, R. R., Ling, L. Y., Riaño‐Pachón, D. M., Rivera, C., Brandão, T. B., Gouvêa, A. F., Santos‐Silva, A. R., Coletta, R. D., et al. (2015) · Scientific Reports · doi:10.1038/srep16305 · Cited by 166
Chang, J., Kim, Y., & Kwon, H. J. (2016) · Natural Product Reports · doi:10.1039/c5np00107b · Cited by 162
Sahoo, B. M., Ravi Kumar, B. V. V., Sruti, J., Mahapatra, M. K., Banik, B. K., & Borah, P. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.628144 · Cited by 137
“Repurpose DB explores the details about disease conditions, side effects, and drug-targets interactions (Wishart et al., 2006; Lamb, 2007).”
BackgroundBhatla, T., Wang, J., Morrison, D. J., Raetz, E. A., Burke, M. J., Brown, P. A., & Carroll, W. L. (2012) · Blood · doi:10.1182/blood-2012-01-401687 · Cited by 158
Tan, B. S., Tiong, K. H., Choo, H. L., Fei-Lei Chung, F., Hii, L.-W., Tan, S. H., Yap, I. K., Pani, S., Khor, N. T., Wong, S. F., et al. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.191 · Cited by 136
“1 (Santa Clara, CA, USA), Gene Set Enrichment Analysis (Broad Institute of Harvard and MIT, MA, USA)67 and the Connectivity Map.48 All microarray expression data have been deposited in the National Center for Biotechnology Information’s Gene Expression Omnibus (GEO series accession number: GSE65967).”
BackgroundMethodInfluentialFutureTox II: In vitro Data and In Silico Models for Predictive Toxicology
Knudsen, T. B., Keller, D. A., Sander, M., Carney, E. W., Doerrer, N. G., Eaton, D. L., Fitzpatrick, S. C., Hastings, K. L., Mendrick, D. L., Tice, R. R., et al. (2015) · Toxicological Sciences · doi:10.1093/toxsci/kfu234 · Cited by 132
“Gene expression data can also be used to generate a connectivity map for toxicants, in a similar manner as described by Lamb and colleagues for pharmaceuticals (Lamb, 2007; Peck et al., 2006), and such data can be used to confirm predicted toxicity of chemical analogs.”
MethodcanSAR: an updated cancer research and drug discovery knowledgebase
Tym, J. E., Mitsopoulos, C., Coker, E. A., Razaz, P., Schierz, A. C., Antolin, A. A., & Al-Lazikani, B. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1030 · Cited by 140
Bioinformatics in translational drug discovery
Wooller, S. K., Benstead-Hume, G., Chen, X., Ali, Y., & Pearl, F. M. G. (2017) · Bioscience Reports · doi:10.1042/bsr20160180 · Cited by 147
Alternatives to animal testing: current status and future perspectives
Liebsch, M., Grune, B., Seiler, A. E. M., Butzke, D., Oelgeschläger, M., Pirow, R., Adler, S., Riebeling, C., & Luch, A. (2011) · Archives of Toxicology · doi:10.1007/s00204-011-0718-x · Cited by 148
“An approach to predict the target effects of a substance is the Connectivity Map (Fig. 10) ( Lamb 2007 ).”
BackgroundA Quantitative Approach to Screen for Nephrotoxic Compounds In Vitro
Adler, M., Ramm, S., Hafner, M., Muhlich, J. L., Gottwald, E. M., Weber, E., Jaklic, A., Ajay, A. K., Svoboda, D., Auerbach, S., et al. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015010060 · Cited by 123
Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer
Abazeed, M. E., Adams, D. J., Hurov, K. E., Tamayo, P., Creighton, C. J., Sonkin, D., Giacomelli, A. O., Du, C., Fries, D. F., Wong, K.-K., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1616 · Cited by 124
“generated from human cancer cell lines treated with different chemicals (31, 32).”
Kim, J., & Orkin, S. H. (2011) · Genome Medicine · doi:10.1186/gm291 · Cited by 123
“In practice, the Connectivity Map database is interrogated with a gene expression signature of interest to ask whether the signature resembles the action of a perturbagen on the reference cells.”
MethodInfluentialNon-kinase targets of protein kinase inhibitors
Munoz, L. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.266 · Cited by 135
Network-Based Drug-Target Interaction Prediction with Probabilistic Soft Logic
Fakhraei, S., Huang, B., Raschid, L., & Getoor, L. C. (2014) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2014.2325031 · Cited by 131
Gene Expression Signature Analysis Identifies Vorinostat as a Candidate Therapy for Gastric Cancer
Claerhout, S., Lim, J. Y., Choi, W., Park, Y.-Y., Kim, K., Kim, S.-B., Lee, J.-S., Mills, G. B., & Cho, J. Y. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024662 · Cited by 117
“Although the Connectivity Map contains more than 7000 expression profiles representing 1,309 compounds, its approach still deals with some limitations such as the limited amount of cell line data (MCF7, PC3, etc) and the ignorance of microenvironmental influences from the human body [16].”
BackgroundMethodInfluentialIskar, M., Zeller, G., Blattmann, P., Campillos, M., Kuhn, M., Kaminska, K. H., Runz, H., Gavin, A., Pepperkok, R., van Noort, V., et al. (2013) · Molecular Systems Biology · doi:10.1038/msb.2013.20 · Cited by 118
Slonim, D. K., Koide, K., Johnson, K. L., Tantravahi, U., Cowan, J. M., Jarrah, Z., & Bianchi, D. W. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903909106 · Cited by 117
“In an attempt to further confirm the importance of these functional processes, we used the Connectivity Map (17, 18) to identify compounds whose molecular signatures either mimic or counteract that of DS.”
MethodNiu, Y., Lin, Z., Wan, A., Sun, L., Yan, S., Liang, H., Zhan, S., Chen, D., Bu, X., Liu, P., et al. (2021) · Hepatology · doi:10.1002/hep.31846 · Cited by 115
“S8A).”
MethodNeggers, J. E., Kwanten, B., Dierckx, T., Noguchi, H., Voet, A., Bral, L., Minner, K., Massant, B., Kint, N., Delforge, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02349-8 · Cited by 112
Biomarkers intersect with the exposome
Rappaport, S. M. (2012) · Biomarkers · doi:10.3109/1354750x.2012.691553 · Cited by 114
“Although the transcriptome (R) reflects effects of environmental factors (Gibson 2008), and with sufficient cataloguing of reference chemicals might offer clues regarding important exposures (Lamb 2007), it would generally be of secondary interest in identifying molecular biomarkers.”
A Gene Signature-Based Approach Identifies mTOR as a Regulator of p73
Rosenbluth, J. M., Mays, D. J., Pino, M. F., Tang, L. J., & Pietenpol, J. A. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00305-08 · Cited by 112
“One of the striking findings from the completion of the Connectivity Map was the extent to which connections could be made across different cell lines and tissues (60, 61).”
BackgroundResultSun, R. W., Lok, C., Fong, T. T., Li, C. K.-L., Yang, Z. F., Zou, T., Siu, F., & Che, C. (2013) · Chemical Science · doi:10.1039/c3sc21972k · Cited by 113
Pickart, L., Vasquez-Soltero, J. M., & Margolina, A. (2012) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2012/324832 · Cited by 108
“used a repository of transcriptional responses to compounds, the Connectivity Map (cMap) [60], and MANTRA software (http://mantra.”
MethodMolecular Dissection of Microsatellite Instable Colorectal Cancer
Vilar, E., & Tabernero, J. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0471 · Cited by 111
Weston, D. J., Gunter, L. E., Rogers, A., & Wullschleger, S. D. (2008) · BMC Systems Biology · doi:10.1186/1752-0509-2-16 · Cited by 111
“[22], and is currently used to connect the disease state of an organism with the underlying genes and possible drug treatments [23].”
BackgroundA STAT3-based gene signature stratifies glioma patients for targeted therapy
Tan, M. S. Y., Sandanaraj, E., Chong, Y. K., Lim, S. W., Koh, L., Ng, W. H., Tan, N. S., Tan, P. B. O., Ang, B. T., & Tang, C. (2019) · Nature Communications · doi:10.1038/s41467-019-11614-x · Cited by 120
Managing the sequence-specificity of antisense oligonucleotides in drug discovery
Hagedorn, P., Hansen, B. R., Koch, T., & Lindow, M. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx056 · Cited by 119
Ketola, K., Vainio, P., Fey, V., Kallioniemi, O., & Iljin, K. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0368 · Cited by 116
“To identify drugs with similar or opposite effects on gene expression, Connectivity Map 02 was used (18).”
MethodWang, C., Chiao, C.-C., Phan, N. N., Li, C.-Y., Sun, Z., Jiang, J., Hung, J., Chen, Y., Yen, M., Weng, T.-Y., et al. (2020) · PubMed · Cited by 124
van Noort, V., Schölch, S., Iskar, M., Zeller, G., Ostertag, K., Schweitzer, C., Werner, K., Weitz, J., Koch, M., & Bork, P. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3540 · Cited by 104
Identifying Network of Drug Mode of Action by Gene Expression Profiling
Iorio, F., Tagliaferri, R., & Bernardo, D. D. (2009) · Journal of Computational Biology · doi:10.1089/cmb.2008.10tt · Cited by 101
“We obtained the network by analyzing a public dataset of genome-wide GEPs, the Connectivity Map (cMap), consisting of expression profiles from five different human cell lines treated with 1309 different compounds, at different concentrations (Lamb, 2007; Lamb et al., 2006).”
Polypharmacology in Drug Discovery: A Review from Systems Pharmacology Perspective
Zhang, W., Bai, Y., Wang, Y., & Xiao, W. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666160224142812 · Cited by 112
The Mycobacterium tuberculosis Drugome and Its Polypharmacological Implications
Kinnings, S., Xie, L., Fung, K. H., Jackson, R. M., Xie, L., & Bourne, P. E. (2010) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000976 · Cited by 109
“In recent years, several computational methodologies have been developed to predict drug-target networks based on ligand chemistry [4–6], phenotypic changes resulting from drug perturbation [7–9], or a combination of chemical features of drugs and sequence features of protein targets [10–12].”
BackgroundLv, C., Wu, X., Wang, X., Su, J., Zeng, H., Zhao, J., Lin, S., Liu, R., Li, H., Li, X., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-00535-8 · Cited by 117
He, J., Qi, W., Wang, L., Tian, J., Jiao, P., Liu, G., Ye, W., & Liao, M. (2012) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.12035 · Cited by 104
“[30] [31] [32] [33] [34] [35] [36] [37] [38] The pre-treatment and simultaneous treatment with these compounds relative to time of infection did not result in significant antiviral activity.”
BackgroundCuproptosis: mechanisms and nanotherapeutic strategies in cancer and beyond
Mao, L., Lu, J., Wen, X., Song, Z., Sun, C., Zhao, Y., Huang, F., Chen, S., Jiang, D., Che, W., et al. (2025) · Chemical Society Reviews · doi:10.1039/d5cs00083a · Cited by 109
Parkin Pathway Activation Mitigates Glioma Cell Proliferation and Predicts Patient Survival
Yeo, C. W. S., Ng, F. S. L., Chai, C., Tan, J. M. M., Koh, G. R. H., Chong, Y. K., Koh, L. W. H., Foong, C. S. F., Sandanaraj, E., Holbrook, J. D., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3060 · Cited by 97
“As parkin pathway activation would be better represented by a collective set of genes rather than a single gene, we adapted the Connectivity Map, a rank-based patternmatching approach that was recently successfully applied to determine the degree of oncogenic pathway activation in gastric cancer (29, 30).”
Towards precision medicine for pain: diagnostic biomarkers and repurposed drugs
Niculescu, A. B., Le-Niculescu, H., Levey, D. F., Roseberry, K., Soe, K. C., Rogers, J., Khan, F., Jones, T., Judd, S., McCormick, M. A., et al. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0345-5 · Cited by 111
Ding, J., Blencowe, M., Nghiem, T., Ha, S.-M., Chen, Y.-W., Li, G., & Yang, X. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab405 · Cited by 97
Jin, G., Fu, C., Zhao, H., Cui, K., Chang, J. C., & Wong, S. T. C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2333 · Cited by 104
“A number of approaches have recently been developed for off-target repositioning by using gene signatures (4-7), i.”
The Chemical Basis of Pharmacology
Keiser, M. J., Irwin, J. J., & Shoichet, B. K. (2010) · Biochemistry · doi:10.1021/bi101540g · Cited by 94
“Using theirMode of Action by Network Analysis (MANTRA) method, the authors leveraged the ConnectivityMap (49, 50) collection to group drugs into “communities” by similarities in their patterns of specific transcriptional responses.”
MethodPrecision medicine for suicidality: from universality to subtypes and personalization
Niculescu, A. B., Le-Niculescu, H., Levey, D. F., Phalen, P. L., Dainton, H. L., Roseberry, K., Niculescu, E. M., Niezer, J. O., Williams, A., Graham, D. L., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.128 · Cited by 93
Tan, B. S., Kang, O., Mai, C., Tiong, K. H., Khoo, A. S. B., Pichika, M. R., Bradshaw, T. D., & Leong, C. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.04.014 · Cited by 101
Amelio, I., Gostev, M., Knight, R. A., Willis, A. E., Melino, G., & Antonov, A. V. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.9 · Cited by 101
“In addition, multiple statistical issues exist as to how to determine precise estimates of statistical significance and false-positive rates.(24,25) Drug signatures implemented in DRUGSURV do not have these limitations, although for many drugs our current knowledge about targets is incomplete.”
BackgroundMethodDrug repurposing: a better approach for infectious disease drug discovery?
Law, G. L., Tisoncik-Go, J., Korth, M. J., & Katze, M. G. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.08.004 · Cited by 90
“[7,9] was used to compare a compendium of 164 known drug compounds in cMap to an IBD-specific gene expression signature derived from 176 datasets available in Gene Expression Omni-bus (GEO).”
Method
Metadata
- Authors
- Lamb, J.
- Affiliations
- Broad Institute (US)
- Corresponding author
- Lamb, Justin
- Venue
- Nature Reviews Cancer
- Published
- 2007-01
- Volume
- 7
- Issue
- 1
- Pages
- 54-60
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2029980980
- Semantic Scholar
- d1610ee5045d33be16a9a72a514fea537ba46306
- Cited by
- 945
- References
- 66
- Citations by year
- 2026: 11 · 2025: 29 · 2024: 75 · 2023: 54 · 2022: 56 · 2021: 100 · 2020: 79 · 2019: 64 · 2018: 60 · 2017: 52 · 2016: 58 · 2015: 57 · 2014: 42 · 2013: 49 · 2012: 56
- FWCI
- 1.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Broad Institute
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Keywords
- Connectivity Map, gene-disease association, drug repurposing, gene expression profiling, cancer research, drug discovery
- MeSH terms
- Algorithms, Animals, Gene Expression Regulation, Humans, Information Services, Models, Biological, Models, Genetic, Neoplasms, Phenotype, Software, Information Storage and Retrieval, Genome, Computational Biology, Biomedical Research
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.